Oncology Institute (NASDAQ:STLN) Stock Jumps 6.1% - Still a Buy?

Key Points

• Oncology Institute shares rose 6.1% to $6.56, though trading volume was 92% below the stock’s average daily volume.
• Analyst sentiment is broadly positive: four analysts rate the stock Buy and one rates it Sell, resulting in a “Moderate Buy” consensus and an average price target of $8.50.
• The company reported a quarterly loss of $0.08 per share but exceeded revenue expectations with $161.28 million in revenue; insider activity was mixed, with a major shareholder buying shares while a director sold a substantial stake.

Oncology Institute, Inc. (NASDAQ:STLN - Get Free Report) shares traded up 6.1% during mid-day trading on Friday. The stock traded as high as $6.56 and last traded at $6.56. 133,504 shares were traded during mid-day trading, a decline of 92% from the average daily volume of 1,771,716 shares. The stock had previously closed at $6.18.

Analysts Set New Price Targets

STLN has been the topic of several analyst reports. Weiss Ratings started coverage on shares of Oncology Institute in a research report on Thursday, August 6th. They set a "sell (d-)" rating on the stock. Needham & Company LLC boosted their price target on Oncology Institute from $5.00 to $7.00 and gave the stock a "buy" rating in a research report on Wednesday, June 17th. BTIG Research boosted their price target on Oncology Institute from $8.00 to $9.00 and gave the stock a "buy" rating in a research report on Thursday, July 9th. Finally, Lake Street Capital assumed coverage on Oncology Institute in a report on Monday, July 6th. They set a "buy" rating and a $10.00 target price for the company. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $8.50.

Oncology Institute Trading Up 9.1%

The firm has a market capitalization of $666.68 million, a price-to-earnings ratio of -22.45 and a beta of 0.39. The business's 50-day moving average price is $6.37.

Oncology Institute (NASDAQ:STLN - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.08) earnings per share (EPS) for the quarter. The company had revenue of $161.28 million during the quarter, compared to the consensus estimate of $152.80 million. As a group, research analysts forecast that Oncology Institute, Inc. will post -0.21 EPS for the current fiscal year.

Insider Transactions at Oncology Institute

In other Oncology Institute news, major shareholder Jorey Chernett bought 18,000 shares of Oncology Institute stock in a transaction dated Tuesday, July 21st. The stock was bought at an average cost of $5.27 per share, with a total value of $94,860.00. Following the completion of the acquisition, the insider directly owned 10,648,858 shares in the company, valued at approximately $56,119,481.66. The trade was a 0.17% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Brad Hively sold 298,853 shares of the business's stock in a transaction on Friday, August 21st. The stock was sold at an average price of $6.51, for a total value of $1,945,533.03. Following the completion of the transaction, the director directly owned 411,976 shares in the company, valued at approximately $2,681,963.76. This represents a 42.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Oncology Institute

Several institutional investors have recently bought and sold shares of the company. R Squared Ltd increased its position in shares of Oncology Institute by 42.7% in the first quarter. R Squared Ltd now owns 16,353 shares of the company's stock worth $50,000 after purchasing an additional 4,891 shares during the last quarter. Legal & General Group Plc purchased a new position in Oncology Institute in the 2nd quarter worth approximately $41,000. AMG National Trust Bank bought a new position in shares of Oncology Institute in the 2nd quarter worth $54,000. Engineers Gate Manager LP bought a new position in shares of Oncology Institute in the 2nd quarter worth $67,000. Finally, Fermata Advisors LLC purchased a new stake in shares of Oncology Institute during the 2nd quarter valued at $70,000. Hedge funds and other institutional investors own 36.86% of the company's stock.

About Oncology Institute

The Oncology Institute, Inc is a healthcare services company focused on providing specialized cancer care through community-based oncology practices. Its services generally include cancer diagnosis, treatment planning, chemotherapy and other infusion therapies, radiation referrals, supportive care, and ongoing monitoring for patients with cancer.

The company's care model is designed to integrate oncologists, advanced practice providers, nurses, and other healthcare professionals while emphasizing coordinated and accessible treatment outside traditional hospital settings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.